DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Actos (Pioglitazone Hydrochloride) - Summary

 

-- advertisement --

ACTOS SUMMARY

ACTOS (pioglitazone hydrochloride) is an oral antidiabetic agent that acts primarily by decreasing insulin resistance. ACTOS is used in the management of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus [NIDDM] or adult-onset diabetes). Pharmacological studies indicate that ACTOS improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. ACTOS improves glycemic control while reducing circulating insulin levels.

ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes (non-insulin-dependent diabetes mellitus, NIDDM). ACTOS is indicated for monotherapy. ACTOS is also indicated for use in combination with a sulfonylurea, metformin, or insulin when diet and exercise plus the single agent does not result in adequate glycemic control.

Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise. These efforts are important not only in the primary treatment of type 2 diabetes, but also to maintain the efficacy of drug therapy.

ACTOS NEWS HIGHLIGHTS

Media Articles Related to Actos (Pioglitazone)

Health Tip: Getting Calcium If You're Lactose Intolerant
Source: MedicineNet Lactose Intolerance Specialty [2008.06.12]

Lactose Intolerance
Source: MedicineNet Celiac Disease Specialty [2008.05.08]

More Broken Bones With Actos, Avandia
Source: MedicineNet pioglitazone Specialty [2008.04.29]

Health Tip: Living With Lactose Intolerance
Source: MedicineNet Lactose Intolerance Specialty [2007.12.19]

Lactose Tolerance Test
Source: MedicineNet Stool Acidity Test Specialty [2002.04.24]

more>>

Published Studies Related to Actos (Pioglitazone)

Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. [2008.07]

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. [2008.05]

Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. [2008.05]

Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. [2008.04.24]

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. [2008.04.22]

more>>

Clinical Trials Related to Actos (Pioglitazone)

A Portion-Controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS [Active, not recruiting]

Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg [Completed]

Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg [Completed]

A Study to Evaluate SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone, or Pioglitazone HCl Alone for the Treatment of Type 2 Diabetes [Active, not recruiting]

Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE) [Completed]

more>>

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008